The electrical, electronics and computer revolutions already lost steam and fizzled out, and many foresee genetic engineering as the next most dominant and significant field of endeavor this century and this is becoming a reality as gene editing is coming to fore in the realms of the medical world.
Many moons back gene editing was considered to be impossible and considered as a mere science fiction, but this has changed dramatically. To date, Massachusetts Institute of Technology (MIT) and University of California, Berkeley (UC Berkeley) are now disputing over rights to gene editing technology according to sources.
Gene editing has already started to make its presence felt as it is becoming the source of some internationally important disputes between prominent and respected scientists worldwide.
Scientists who are well-acquainted with the gene editing tech which is also called as CRISPR-Cas9 stated that this technology could break the boundaries of present day medicine. At the present time, MIT and UC Berkeley are both clashing over rights to CRISPR-Cas9 and the debate has escalated to international significance.
Conversely, MIT and UC Berkeley are not the only universities which are connected over the case of the patent rights to the new gene editing tech.
At the outset, the judges who have been connected with this matter and who represented the United States Patent and Trademark Office have handed over the patent rights to the CRISPR-Cas9 to the Broad Institute of MIT and Harvard.
However, the decision was not well-accepted by the researchers at the UC Berkeley and hence they have just asked the United States Patent and Trademark Office to re-evaluate their decision.
The lawyers who are taking the cudgels for University of California, Berkeley have said that the official distribution of patent rights over the CRISPR-Cas9 is doubtful and need to be reconsidered by the authorities.
At present, the terms of the law regard the research team which has been spearheaded by Jennifer Doudna as the agent that should have given the patent rights over the new gene editing technology. A professor at the University of California, Berkeley, Doudna teaches chemistry and molecular and cell biology.
It appears like the decision whipped up by the authorities concerning the patent rights over the new gene editing technology will likely be questionable again.
But what really is the subject of dispute, that is, the CRISPR-Cas9 technology is all about.
Brett Staahl, a postdoctoral researcher who is working together with other scientists connected to Doudna’s lab said that, “The CRISPR-Cas9 technology functions as a precise and programmable scissors.”
By harnessing such technology, it appears like scientists will soon be able to come up with a better procedure of modifying DNA sequences than the ones that were employed before CRISPR-Cas9 appeared in the limelight. The dependability of such process would be further enhanced by employing new gene editing technology.